Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

10.55 +0.36 (+3.53%)
Streaming Delayed Price Updated: 3:05 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 123,447
Open 10.48
Bid (Size) 10.55 (400)
Ask (Size) 10.56 (300)
Prev. Close 10.19
Today's Range 10.46 - 10.59
52wk Range 6.280 - 20.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
From Telix Pharmaceuticals Limited
Via GlobeNewswire

Performance

YTD
+38.5%
+38.5%
1 Month
+20.3%
+20.3%
3 Month
+38.5%
+38.5%
6 Month
-3.0%
-3.0%
1 Year
-42.3%
-42.3%

More News

Read More
News headline image
The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
Via Finterra
Topics Economy Initial Public Offering
News headline image
Telix and Regeneron Announce Strategic Radiopharma Collaboration
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Regeneron and Telix Announce Strategic Radiopharma Collaboration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Accepts NDA for TLX101-Px (Pixclara®)
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Strengthens Board with Additional Director Appointments
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Appoints David Gill as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Investor Education Webinar
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Telix to Participate in Oppenheimer and TD Cowen Conferences
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Full Year Results 2025 Investor Webcast Notification
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Deadline Soon: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire

Frequently Asked Questions

Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 10.55
When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 04/24/26 03:05 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.